ArticleFrontiers in endocrinology2025
Case Report: Exogenous insulin antibody syndrome complicated with chronic renal failure and long-term history of type 2 diabetes: report of two cases.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insulin autoimmune syndrome (IAS), a rare condition caused by an endogenous insulin-induced autoimmune reaction, is characterized by recurrent hypoglycemic episodes, positive insulin autoantibodies (IAAs), and high serum insulin levels. However, recent studies have demonstrated that exogenous insulin administration can also lead to similar clinical manifestations and have proposed the concept of non-classical IAS. This article reports two cases of exogenous insulin antibody syndrome (EIAS), analyzes their clinical features, and describes our therapeutic approach. Case presentation: The first patient was an 83-year-old male with a 15-year history of type 2 diabetes, while the second patient was an 86-year-old male with a 20-year history of type 2 diabetes. Both patients had a history of exogenous insulin use and chronic renal failure. On admission, they exhibited alternating episodes of hypoglycemia and hyperglycemia. Laboratory tests revealed hyperinsulinemia (insulin >600.00 μIU/ml in both patients), a dissociation phenomenon between blood insulin and C-peptide levels, and positive IAAs. Conclusion: In both patients, glycemic fluctuations resolved following insulin discontinuation and the initiation of dorzagliatin, confirming the diagnosis of EIAS. In type 2 diabetic patients with unexplained hypoglycemic and hyperglycemic episodes with a history of exogenous insulin use, pancreatic function and the autoimmune antibody spectrum should be comprehensively evaluated to rule out EIAS and provide an accurate diagnosis and guide treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.